Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven
Executive Summary
Eisai’s request to forego Phase IV studies for its anticancer, Halaven, has been turned down by an Indian expert panel, which has reminded the Japanese company of the conditional marketing authorization previously granted for the product. Eisai, for its part, now says it will follow the “necessary requirements” set out by the Indian regulator.